September 27, 2012, Reston, VA and Wellesley, MA Leading middle-market investment banking firm, WWC Securities, LLC announced today that it has changed its name to Outcome Capital, LLC and has added a life sciences and healthcare practice to complement its current and successful practice in the IT services, software and technology sectors. The Firm is opening a new office in Wellesley, MA where its life science and healthcare practice will be based.
Outcome Capital employs a unique market-driven and capital-efficient approach to identify key value and risk drivers and to align strategic objectives with transaction opportunities. The firm’s multi-disciplinary team leverages its sector knowledge to deliver differentiated transaction advisory services, filling a void in the market. Too often, middle-market companies are forced to choose between a niche M&A advisor or a bulge bracket firm when seeking strategic financial advisors. Outcome offers the best of both worlds. In the past 18 months, the partners of Outcome Capital have closed over ten middle-market transactions including mergers and acquisitions and the placement of private equity and debt.
“We believe the name change to Outcome Capital reflects our focus on the exceptional service we provide for our clients,” stated Jonathan Wallace, Partner, Outcome Capital. “The team we are bringing on in Boston have demonstrated that they can deliver results across the life science industry and will make a great addition.”
Partners Arnold Freedman and Dr. Oded Ben-Joseph, formerly of Boston Equity Advisors, will lead Outcome Capital’s healthcare practice. Recently, Dr. Ben-Joseph and Mr. Freedman were exclusive advisors to regenerative medicine company Histogenics Corporation, completing an acquisition of ProChon Biotech and a $49 million round of financing to support commercial development of its cartilage repair products.
“We are passionate about innovation with a mission to facilitate significant positive impact on our client companies,” said Dr. Oded Ben-Joseph, Partner, Outcome Capital. “We are interested in engaging companies that possess a portfolio of transformative assets, a bold vision and a desire to achieve excellence. We take pride in our ability to assist our clients, aligning business objectives with strategic opportunities and transactional expertise”.
About Outcome Capital
Outcome Capital, LLC is a multifaceted services, technology, and life sciences investment banking firm that provides middle-market growth companies with an innovative client-specific approach to private equity and merger and acquisition advisory services. The firm assists boards of directors and management teams in building value, navigating the financial markets, and implementing strategies for success.
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing round to support its European commercialization. Outcome Capital served as the exclusive strategic and financial advisor to the company. ELIOS’ implant-free, minimally invasive Excimer Laser Trabeculostomy glaucoma procedure is approved […]Read More
Outcome Capital Life Science Market Pulse July 2022 Click to view our LifeSciences Pulse NewsletterDownload